Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
AbbVie's Elagolix Meets Primary Endpoint in Phase II Study
by Zacks Equity Research
AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
by Zacks Equity Research
We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.
Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.
5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now
by Zacks Equity Research
Lily carries a Zacks Rank #2 (Buy).
Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.
Bristol-Myers (BMY), Incyte to Advance Clinical Program
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
by Zacks Equity Research
Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.
Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
by Arpita Dutt
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
Infinity Pharma Focuses on Cancer Drug: Competition Looms
by Zacks Equity Research
We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
by Zacks Equity Research
Glaxo carries a Zacks Rank #2 (Buy).
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
by Sweta Killa
President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.
Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.
Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
by Zacks Equity Research
Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.
Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
by Arpita Dutt
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.